new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12016016670806/16/16 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
22016012914005/12/16 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
32016013033305/12/16 Chimeric and humanized anti-histone antibodies
42016012097605/05/16 Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
52016009593904/07/16 Neoadjuvant use of antibody-drug conjugates
62016009041303/31/16 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
72016009042303/31/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
82016008200303/24/16 Immunoconjugates with an intracellularly-cleavable linkage
92016006988503/10/16 Detection of early-stage pancreatic adenocarcinoma
102016006070703/03/16 Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
112016004562602/18/16 Methods and compositions for improved labeling of targeting peptides
122016003994102/11/16 Immunotherapy of autoimmune disorders using antibodies which target b-cells
132016003200302/04/16 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
142016003200402/04/16 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
152016003200802/04/16 Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
162016002421201/28/16 Humanized anti-hla-dr antibodies
172016000091501/07/16 Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells
182015036698812/24/15 Antibody-drug conjugates and uses thereof
192015036836212/24/15 Anti-histone therapy for vascular necrosis in severe glomerulonephritis
202015034308712/03/15 Class i anti-cea antibodies and uses thereof
212015034457312/03/15 Humanized anti-cd22 antibody
222015032087211/12/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
232015031528911/05/15 Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
242015030624310/29/15 Antibody-sn-38 immunoconjugates with a cl2a linker
252015030624410/29/15 Anthracycline-antibody conjugates for cancer therapy
262015030752410/29/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
272015028326410/08/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
282015025211009/10/15 Anti-cd19 antibodies
292015023997408/27/15 Humanized rfb4 anti-cd22 antibody
302015022419208/13/15 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
312015021699708/06/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
322015021700608/06/15 Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
332015020231907/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
342015020232007/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
352015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
362015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
372015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
382015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
392015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
402015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
412015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
422015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
432015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
442015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
452015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
462015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
472015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
482015016665906/18/15 Humanized l243 antibodies
492015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
502015015096906/04/15 Chimeric and humanized anti-histone antibodies
512015013276805/14/15 Anti-pancreatic cancer antibodies
522015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
532015011127904/23/15 Class i anti-cea antibodies and uses thereof
542015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
552015008648203/26/15 Dye conjugated peptides for fluorescent imaging
562015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
572015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
582015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
592014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
602014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
612014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
622014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
632014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
642014028686109/25/14 Rs7 antibodies
652014023420908/21/14 Chimeric and humanized anti-histone antibodies
662014022717808/14/14 Humanized anti-hla-dr antibodies
672014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
682014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
692014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
702014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
712014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
722014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
732014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
742014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
752014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
762014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
772014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
782014014092405/22/14 Humanized l243 antibodies
792014012003505/01/14 Rs7 antibodies
802014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
812014011286504/24/14 Anti-cd19 antibodies
822014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
832014009925804/10/14 Camptothecin-binding moiety conjugates
842014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
852014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
862014007962903/20/14 Class i anti-cea antibodies and uses thereof
872014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
882014004463902/13/14 Antibody therapy
892014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
902014003754302/06/14 Anti-pancreatic cancer antibodies
912014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
922014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
932014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
942014001719701/16/14 Anti-cd19 antibodies
952014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
962013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
972013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
982013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
992013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1002013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1012013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1022013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1032013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
1042013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1052013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
1062013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
1072013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1082013015669106/20/13 Antibody therapy
1092013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
1102013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1112013012191305/16/13 Anti-cd19 antibodies
1122013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
1132013009503404/18/13 Anti-cd74 immunoconjugates and methods
1142013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
1152013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
1162013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
1172013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1182013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
1192013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1202013003986102/14/13 Dye conjugated peptides for fluorescent imaging
1212013003449202/07/13 Class i anti-cea antibodies and uses thereof
1222012032856412/27/12 Camptothecin-binding moiety conjugates
1232012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
1242012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
1252012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1262012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1272012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1282012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1292012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1302012018954207/26/12 Anti-cd19 antibodies
1312012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1322012018355007/19/12 Therapeutic using a bispecific antibody
1332012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1342012014137206/07/12 Rs7 antibodies
1352012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1362012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1372012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1382012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1392012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1402012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1412012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1422012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1432012003979702/16/12 Antibody therapy
1442012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1452012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1462011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1472011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1482011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1492011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1502011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1512011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1522011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1532011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1542011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1552011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1562011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1572011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1582011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1592011022364509/15/11 Multivalent carriers of bi-specific antibodies
1602011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1612011018908508/04/11 Antibody therapy
1622011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1632011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1642011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1652011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1662011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1672011011710505/19/11 Method of treating immune disease using b-cell antibodies
1682011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1692011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1702011007015503/24/11 Anti-cd74 immunoconjugates and methods
1712011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1722011006465303/17/11 Class i anti-cea antibodies and uses thereof
1732011005248903/03/11 Anti-cd19 antibodies
1742010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1752010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1762010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1772010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1782010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1792010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1802010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1812010022117509/02/10 Antibody therapy
1822010022117709/02/10 Rs7 antibodies
1832010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1842010020296108/12/10 D-amino acid peptides
1852010019626608/05/10 Humanized anti-hla-dr antibodies
1862010019626708/05/10 Humanized l243 antibodies
1872010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1882010018964107/29/10 Novel strategies for improved cancer vaccines
1892010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1902010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1912010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1922010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1932010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1942010006813603/18/10 Anti-cd19 antibodies
1952010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1962010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1972010001504601/21/10 Camptothecin-binding moiety conjugates
1982010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1992010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
2002010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
2012009030458012/10/09 Anti-pancreatic cancer antibodies
2022009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2032009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
2042009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
2052009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
2062009025273110/08/09 Multivalent carriers of bi-specific antibodies
2072009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
2082009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2092009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
2102009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
2112009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
2122009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
2132009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
2142009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
2152009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
2162009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
2172009009259804/09/09 Antibody therapy
2182010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
2192010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###